第1章 全球人類乳突病毒(HPV)感染治療藥市場概要

第2章 人類乳突病毒(HPV)感染治療藥臨床實驗分析:Phase、國別

第3章 已上市人類乳突病毒(HPV)治療藥簡介

第4章 未開發·中止的HPV治療藥簡介

未開發

中止

市場撤退

第5章 競爭情形

Advanced Viral Research

Biogen Idec

BioSphings

EyeGene

Helix BioPharma

Inviragen

MedImmune

Merck & Co

Valeant Pharmaceuticals

圖表清單

目錄

Currently there is significant amount of research being undertaken to study
the process of HPV infection causing precancerous changes in normal cells.
Also, methods to prevent and manage this situation are also being analyzed. A
majority of these studies were previously focusing on cervical cells in women.
But in recent years, the realm of research has been extended to other tissues
also in which HPV may cause cancer, such as the oropharynx and anus. Also,
many organizations are analyzing the use of second-generation preventive
vaccines along with therapeutic HPV vaccines, which could possibly prevent the
development of cancer among women previously infected with HPV. Such an
“ideal” vaccine strategy would combine a preventive and
therapeutic vaccine, which would help in a major way.

The mechanism of the HPV vaccines is similar to the other immunizations which
help in protecting against viral infections. It has been observed and analyzed
that the unique surface components of HPV have the capability to create an
antibody response which could possibly protect the human body against
infection. These components could thus be used as a basis of the vaccine.
There are only 2 HPV vaccines which are currently marketed across the globe.
Both these vaccines are prepared using the recombinant technology, which is
taken from purified L1 structural proteins which self assemble to form HPV
type-specific empty shells or virus-like particles (VLPs).

Since there are no therapeutic HPV vaccines available at present which have
proved their efficiency in the clinical trials, there is still a lot of work
which is required in this field, thus opening a large window of opportunities.
There have been some technological advancements in the past 4-5 years. The
future is also likely to continue to witness similar technological and medical
success in terms of new drugs and efficient vaccines, with the help of
adequate funding. Certain developments like a new treatment to reduce
transmissibility in drug users and new efforts to strengthen the immune system
have the potential to develop further and provide better healthcare services
to the patients in the future. Thus, there needs to be more focus being given
to increasing the knowledge and awareness about HPV infections and the ways
and methods to treat it, either through drugs or through vaccines.